Name Kazuyuki Kitatani, Ph.D. kazuyuki.kitatani*pharm.setsunan.ac.jp (* is @)
Publications ORCID ID
1993-1997 B.S., Kyoto Pharmaceutical University, Kyoto, Japan (Licensed as Pharmacist)
1997-1999 M.S., Graduate School, Kyoto Pharmaceutical University
1999-2002 Ph.D., Graduate School, Kyoto Pharmaceutical University
Position and Employment
2002-2007 Post-doctoral fellow, Yusuf A. Hannun Lab, Department of Biochemistry and Molecular Biology, Medical University of South
Carolina, Charleston, SC, U.S.A.
2007-2008 Instructor, Department of Biochemistry and Molecular Biology, Medical University of South Carolina
2008-2012 Assistant Professor, Department of Clinical Laboratory, Tottori University Hospital, Yonago, Japan
2012-2017 Assistant Professor, Tohoku Medical Megabank Organization/Department of Obstetrics and Gynecology, Tohoku University,
2017-2018 Senior Assistant Professor, Tohoku Medical Megabank Organization/Department of Obstetrics and Gynecology, Tohoku University
2018-Present Associate Professor, Lab. of Immunopharmacology, Setsunan University, Osaka, Japan
1997– The Japanese Biochemical Society
1997– The Pharmaceutical Society of Japan;
2007– The American Society for Biochemistry and Molecular Biology (ASBMB)
2009– The Japanese Conference on the Biochemistry of Lipids (JCBL)
2012– The Japan Society of Obstetrics and Gynecology (JSOG)
2014–2016 Lead guest editor, Mediators of Inflammation
2016-present Editorial board, Journal of Gynecology & Reproductive Medicine
Title 1: Sphingolipid function
Our laboratory is interested in delineating the function of bioactive sphingolipids including ceramide, sphingosine-1-phosphate, and sphingosine. Especially we study on defining the roles of sphingolipids in cell motility and programmed necrosis (necroptosis).
Title 2: Ceramide-centered therapy
We study molecular pharmacology of ceramide nanoliposomes and ceramide-centered therapeutics for cancer and inflammatory diseases.
Title 3: Drug discovery for cancer
Our laboratory has studied chemo-resistance and metastasis in cancer. Cancer develops with chemo-resistance and/or metastasis and defining the regulatory mechanisms gives insight into drug discovery. We focus on addressing the molecular mechanisms and finding the molecular target for cancer treatment. In addition, we are proposing necroptosis as a target for cancer therapy and focus on discovering necroptosis-based antitumor reagents.